(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) applauds the Energy and Commerce Subcommittee on Oversight and Investigations for holding today’s hearing on the important issue of rising insulin prices. “Drugmakers are solely responsible for setting and raising prescription
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on reports that twenty-eight drugmakers are set to raise prescription drug prices in 2019: “Today’s news underscores the fact that drugmakers alone set
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on legislation, the “Patient Right to Know Drug Prices Act” and the “Know the Lowest Price Act,” introduced today in the Senate: “We support the patient always
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is announcing the launch of a TV and digital advertising campaign on President Trump’s Executive Order to revive the so-called rebate rule. The campaign warns policymakers and the public that the
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the decision to raise Gleostine’s price from $50 to $768: “The drug company’s decision to raise the price of the forty-year-old drug Gleostine by 1400% –
For millions of Americans, the prescription drug delivery system works: people, for the most part, can access the medications they need when they need them, and at the cost they expect and can afford. But “millions of Americans” does not
(Washington, D.C.) — As Congress begins to examine high prescription drug prices, the Pharmaceutical Care Management Association (PCMA) sent letters to several congressional committees highlighting the value pharmacy benefit managers (PBMs) provide to patients and payers as well as outlining
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the U.S. House of Representatives’ vote on prescription drug price transparency legislation: “PBMs support increasing transparency across the entire prescription drug supply
©2024 PCMA. All Rights Reserved.
